Share Price and Basic Stock Data
Last Updated: February 6, 2026, 8:29 pm
| PEG Ratio | 2.79 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Beta Drugs Ltd operates in the pharmaceuticals sector and has shown a consistent upward trend in its revenue. For the fiscal year ending March 2025, the company reported sales of ₹362 Cr, a significant increase from ₹296 Cr in the previous fiscal year, indicating a year-on-year growth of approximately 22.3%. The quarterly sales figures also reflect this positive trajectory, with revenue rising from ₹115 Cr in March 2023 to ₹141 Cr in September 2023. The company’s ability to scale its operations is evident, as it has strategically increased its sales from ₹51 Cr in September 2020 to ₹141 Cr in September 2023. This growth is attributed to the company’s robust product pipeline and market expansion efforts. The overall market capitalization of Beta Drugs Ltd stands at ₹1,434 Cr, further emphasizing its position in the industry. The revenue from operations per share increased to ₹358.96, showcasing efficient utilization of equity capital.
Profitability and Efficiency Metrics
Beta Drugs Ltd reported a net profit of ₹42 Cr for the fiscal year ending March 2025, up from ₹36 Cr in the previous year, underlining the company’s strong profitability. The net profit margin stood at 11.70%, slightly lower than the previous year’s 12.32%, indicating a minor compression in profitability amidst rising operational costs. The operating profit margin (OPM) remained stable at 21%, reflecting the company’s operational efficiency despite a rise in expenses, which reached ₹288 Cr in the same fiscal year. The interest coverage ratio (ICR) was recorded at 11.60x, indicating a strong ability to cover interest obligations, which is significantly higher than the typical sector range of 3x-5x. Moreover, the return on equity (ROE) stood at 25.9%, suggesting effective utilization of shareholders’ funds. The cash conversion cycle (CCC) of 79 days indicates a relatively efficient management of working capital, although it is slightly higher than the previous year’s 68 days, suggesting a need for monitoring inventory and receivables.
Balance Sheet Strength and Financial Ratios
Beta Drugs Ltd’s balance sheet reflects a solid financial position with total assets of ₹436 Cr and total liabilities of ₹488 Cr as of March 2025. The company has reserves amounting to ₹211 Cr, demonstrating a strong retained earnings position to support future growth. However, the total debt stands at ₹146 Cr, leading to a debt-to-equity ratio of 0.67, which indicates a moderate level of leverage compared to typical sector norms. The current ratio is reported at 3.22x, significantly above the ideal benchmark of 1.5x, suggesting strong liquidity and the ability to meet short-term obligations. The return on capital employed (ROCE) was recorded at 27%, which is robust and indicates efficient use of capital in generating profits. The price-to-book value (P/BV) stood at 9.76x, suggesting that the market values the company at a premium relative to its book value, a common characteristic in growth-oriented sectors like pharmaceuticals.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Beta Drugs Ltd indicates a stable ownership structure, with promoters holding 66.73% of the equity, reflecting strong management control. The public shareholding stands at 32.07%, with a gradual increase in the number of shareholders from 3,054 in March 2025 to 3,184 by September 2025, indicating growing investor interest. Foreign institutional investors (FIIs) have increased their stake to 0.90%, while domestic institutional investors (DIIs) hold 0.29%. This gradual increase in institutional holdings suggests confidence in the company’s future prospects. However, the relatively low FII and DII participation could be a risk factor, as it may limit the company’s liquidity in the stock market. The consistent shareholding by promoters can be viewed as a positive indicator of their commitment to the company’s long-term vision.
Outlook, Risks, and Final Insight
Looking ahead, Beta Drugs Ltd is well-positioned to leverage its strong sales growth and profitability metrics to capitalize on emerging opportunities in the pharmaceutical sector. The company’s focus on operational efficiency and its robust balance sheet provide a solid foundation for sustainable growth. However, risks include rising operational costs, which could pressure margins, and the need for continued innovation to maintain competitive advantage in a fast-evolving industry. Additionally, the relatively low levels of institutional investment could pose liquidity challenges. Overall, if Beta Drugs Ltd can navigate these risks effectively while continuing to expand its market presence, it has the potential for significant long-term value creation. In scenarios where operational efficiencies improve and market conditions remain favorable, the company could see enhanced profitability and investor confidence, driving further growth in its stock price and market capitalization.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 128 Cr. | 102 | 188/84.3 | 28.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,527 Cr. | 324 | 479/192 | 73.8 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.0 Cr. | 53.9 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,603.26 Cr | 1,093.01 | 42.95 | 202.24 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 47 | 44 | 51 | 65 | 88 | 96 | 112 | 115 | 141 | 154 | 180 | 182 | 204 |
| Expenses | 37 | 36 | 41 | 51 | 68 | 73 | 86 | 88 | 108 | 127 | 141 | 146 | 163 |
| Operating Profit | 9 | 8 | 11 | 14 | 20 | 23 | 27 | 26 | 33 | 27 | 39 | 36 | 41 |
| OPM % | 20% | 19% | 21% | 22% | 23% | 24% | 24% | 23% | 23% | 18% | 22% | 20% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 6 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 7 |
| Depreciation | 2 | 2 | 3 | 4 | 3 | 4 | 5 | 6 | 5 | 4 | 6 | 7 | 8 |
| Profit before tax | 7 | 5 | 7 | 9 | 16 | 18 | 21 | 20 | 27 | 22 | 33 | 24 | 32 |
| Tax % | 27% | 14% | 21% | 30% | 28% | 27% | 25% | 25% | 25% | 25% | 25% | 26% | 25% |
| Net Profit | 5 | 4 | 5 | 7 | 12 | 13 | 16 | 15 | 20 | 17 | 24 | 18 | 24 |
| EPS in Rs | 5.07 | 4.25 | 5.13 | 6.48 | 11.63 | 12.95 | 15.67 | 14.73 | 19.67 | 16.40 | 24.20 | 17.81 | 23.70 |
Last Updated: January 2, 2026, 7:02 am
Below is a detailed analysis of the quarterly data for Beta Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 204.00 Cr.. The value appears strong and on an upward trend. It has increased from 182.00 Cr. (Mar 2025) to 204.00 Cr., marking an increase of 22.00 Cr..
- For Expenses, as of Sep 2025, the value is 163.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 146.00 Cr. (Mar 2025) to 163.00 Cr., marking an increase of 17.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 5.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.00%.
- For Other Income, as of Sep 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 6.00 Cr..
- For Interest, as of Sep 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 8.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 23.70. The value appears strong and on an upward trend. It has increased from 17.81 (Mar 2025) to 23.70, marking an increase of 5.89.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:34 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 386 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 309 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 77 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 6 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 12 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 15 |
| Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 56 |
| Tax % | 1% | -2% | 21% | 27% | 28% | 25% | 25% | 26% | |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 42 |
| EPS in Rs | 7.43 | 8.84 | 9.33 | 11.60 | 24.58 | 30.42 | 36.08 | 42.02 | 41.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 14.29% | 12.50% | 33.33% | 108.33% | 24.00% | 16.13% | 16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1.79% | 20.83% | 75.00% | -84.33% | -7.87% | 0.54% |
Beta Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 25% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 23% |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 87% |
| 3 Years: | 36% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 27% |
| Last Year: | 26% |
Last Updated: September 5, 2025, 12:45 am
Balance Sheet
Last Updated: January 7, 2026, 3:27 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 211 |
| Borrowings | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 146 |
| Other Liabilities | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 121 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 488 |
| Fixed Assets | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 112 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other Assets | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 376 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 488 |
Below is a detailed analysis of the balance sheet data for Beta Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 211.00 Cr.. The value appears strong and on an upward trend. It has increased from 187.00 Cr. (Mar 2025) to 211.00 Cr., marking an increase of 24.00 Cr..
- For Borrowings, as of Sep 2025, the value is 146.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 138.00 Cr. (Mar 2025) to 146.00 Cr., marking an increase of 8.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 121.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 20.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 488.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 436.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 52.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 112.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Mar 2025) to 112.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 347.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 29.00 Cr..
- For Total Assets, as of Sep 2025, the value is 488.00 Cr.. The value appears strong and on an upward trend. It has increased from 436.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 52.00 Cr..
Notably, the Reserves (211.00 Cr.) exceed the Borrowings (146.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | -8.00 | -5.00 | 8.00 | 22.00 | 33.00 | 45.00 | -63.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 82 |
| ROCE % | 18% | 21% | 22% | 36% | 34% | 33% | 27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| Diluted EPS (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| Cash EPS (Rs.) | 54.42 | 48.08 | 42.78 | 33.37 | 19.34 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Revenue From Operations / Share (Rs.) | 358.96 | 307.59 | 236.24 | 191.22 | 120.79 |
| PBDIT / Share (Rs.) | 80.28 | 63.82 | 56.05 | 45.20 | 26.26 |
| PBIT / Share (Rs.) | 67.89 | 53.65 | 45.22 | 37.65 | 19.11 |
| PBT / Share (Rs.) | 56.44 | 50.71 | 42.70 | 35.68 | 16.59 |
| Net Profit / Share (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| NP After MI And SOA / Share (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| PBDIT Margin (%) | 22.36 | 20.74 | 23.72 | 23.63 | 21.73 |
| PBIT Margin (%) | 18.91 | 17.44 | 19.14 | 19.69 | 15.81 |
| PBT Margin (%) | 15.72 | 16.48 | 18.07 | 18.65 | 13.73 |
| Net Profit Margin (%) | 11.70 | 12.32 | 13.52 | 13.50 | 10.09 |
| NP After MI And SOA Margin (%) | 11.70 | 12.32 | 13.52 | 13.50 | 10.09 |
| Return on Networth / Equity (%) | 21.52 | 23.19 | 24.99 | 26.88 | 17.08 |
| Return on Capital Employeed (%) | 20.54 | 30.43 | 32.10 | 33.24 | 22.09 |
| Return On Assets (%) | 9.72 | 14.33 | 15.48 | 15.72 | 9.97 |
| Long Term Debt / Equity (X) | 0.64 | 0.03 | 0.05 | 0.12 | 0.16 |
| Total Debt / Equity (X) | 0.67 | 0.06 | 0.13 | 0.17 | 0.21 |
| Asset Turnover Ratio (%) | 1.05 | 1.31 | 1.27 | 1.09 | 0.82 |
| Current Ratio (X) | 3.22 | 2.10 | 2.03 | 1.98 | 1.99 |
| Quick Ratio (X) | 2.64 | 1.51 | 1.54 | 1.52 | 1.53 |
| Inventory Turnover Ratio (X) | 6.61 | 4.17 | 4.16 | 5.70 | 4.47 |
| Interest Coverage Ratio (X) | 11.60 | 21.76 | 22.31 | 22.88 | 10.43 |
| Interest Coverage Ratio (Post Tax) (X) | 7.72 | 13.92 | 13.72 | 14.07 | 5.85 |
| Enterprise Value (Cr.) | 1909.20 | 1168.47 | 599.62 | 542.92 | 119.61 |
| EV / Net Operating Revenue (X) | 5.27 | 3.95 | 2.64 | 2.95 | 1.03 |
| EV / EBITDA (X) | 23.56 | 19.04 | 11.13 | 12.49 | 4.74 |
| MarketCap / Net Operating Revenue (X) | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| Price / BV (X) | 9.76 | 7.55 | 4.90 | 5.89 | 1.68 |
| Price / Net Operating Revenue (X) | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| EarningsYield | 0.02 | 0.03 | 0.05 | 0.04 | 0.10 |
After reviewing the key financial ratios for Beta Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.42. This value is within the healthy range. It has increased from 48.08 (Mar 24) to 54.42, marking an increase of 6.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 358.96. It has increased from 307.59 (Mar 24) to 358.96, marking an increase of 51.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 80.28. This value is within the healthy range. It has increased from 63.82 (Mar 24) to 80.28, marking an increase of 16.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 67.89. This value is within the healthy range. It has increased from 53.65 (Mar 24) to 67.89, marking an increase of 14.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 56.44. This value is within the healthy range. It has increased from 50.71 (Mar 24) to 56.44, marking an increase of 5.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For PBDIT Margin (%), as of Mar 25, the value is 22.36. This value is within the healthy range. It has increased from 20.74 (Mar 24) to 22.36, marking an increase of 1.62.
- For PBIT Margin (%), as of Mar 25, the value is 18.91. This value is within the healthy range. It has increased from 17.44 (Mar 24) to 18.91, marking an increase of 1.47.
- For PBT Margin (%), as of Mar 25, the value is 15.72. This value is within the healthy range. It has decreased from 16.48 (Mar 24) to 15.72, marking a decrease of 0.76.
- For Net Profit Margin (%), as of Mar 25, the value is 11.70. This value exceeds the healthy maximum of 10. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.70. This value is within the healthy range. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.52. This value is within the healthy range. It has decreased from 23.19 (Mar 24) to 21.52, marking a decrease of 1.67.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.54. This value is within the healthy range. It has decreased from 30.43 (Mar 24) to 20.54, marking a decrease of 9.89.
- For Return On Assets (%), as of Mar 25, the value is 9.72. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 9.72, marking a decrease of 4.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.64, marking an increase of 0.61.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.67, marking an increase of 0.61.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.05. It has decreased from 1.31 (Mar 24) to 1.05, marking a decrease of 0.26.
- For Current Ratio (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 3.22, marking an increase of 1.12.
- For Quick Ratio (X), as of Mar 25, the value is 2.64. This value exceeds the healthy maximum of 2. It has increased from 1.51 (Mar 24) to 2.64, marking an increase of 1.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.61. This value is within the healthy range. It has increased from 4.17 (Mar 24) to 6.61, marking an increase of 2.44.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.60. This value is within the healthy range. It has decreased from 21.76 (Mar 24) to 11.60, marking a decrease of 10.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 13.92 (Mar 24) to 7.72, marking a decrease of 6.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,909.20. It has increased from 1,168.47 (Mar 24) to 1,909.20, marking an increase of 740.73.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.27. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.27, marking an increase of 1.32.
- For EV / EBITDA (X), as of Mar 25, the value is 23.56. This value exceeds the healthy maximum of 15. It has increased from 19.04 (Mar 24) to 23.56, marking an increase of 4.52.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
- For Price / BV (X), as of Mar 25, the value is 9.76. This value exceeds the healthy maximum of 3. It has increased from 7.55 (Mar 24) to 9.76, marking an increase of 2.21.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beta Drugs Ltd:
- Net Profit Margin: 11.7%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.54% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.52% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.8 (Industry average Stock P/E: 42.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.67
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.7%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Nandpur, Baddi Himachal Pradesh 174101 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rahul Batra | Chairperson & Managing Director |
| Mr. Varun Batra | Joint Managing Director |
| Mr. Ashutosh Shukla | Whole Time Director |
| Mr. Balwant Singh | Whole Time Director |
| Mr. Ajay Mahipal | Director |
| Mr. Manmohan Khanna | Independent Director |
| Mr. Rohit Parti | Independent Director |
| Mrs. Monica Jain | Independent Director |
| Mr. Sanjay Sehgal | Independent Director |
| Mr. Lalit Kumar Watts | Independent Director |
FAQ
What is the intrinsic value of Beta Drugs Ltd?
Beta Drugs Ltd's intrinsic value (as of 06 February 2026) is ₹1583.07 which is 14.72% higher the current market price of ₹1,380.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,393 Cr. market cap, FY2025-2026 high/low of ₹2,000/1,362, reserves of ₹211 Cr, and liabilities of ₹488 Cr.
What is the Market Cap of Beta Drugs Ltd?
The Market Cap of Beta Drugs Ltd is 1,393 Cr..
What is the current Stock Price of Beta Drugs Ltd as on 06 February 2026?
The current stock price of Beta Drugs Ltd as on 06 February 2026 is ₹1,380.
What is the High / Low of Beta Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Beta Drugs Ltd stocks is ₹2,000/1,362.
What is the Stock P/E of Beta Drugs Ltd?
The Stock P/E of Beta Drugs Ltd is 30.8.
What is the Book Value of Beta Drugs Ltd?
The Book Value of Beta Drugs Ltd is 219.
What is the Dividend Yield of Beta Drugs Ltd?
The Dividend Yield of Beta Drugs Ltd is 0.00 %.
What is the ROCE of Beta Drugs Ltd?
The ROCE of Beta Drugs Ltd is 27.0 %.
What is the ROE of Beta Drugs Ltd?
The ROE of Beta Drugs Ltd is 25.9 %.
What is the Face Value of Beta Drugs Ltd?
The Face Value of Beta Drugs Ltd is 10.0.